Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F25%3A10504132" target="_blank" >RIV/00064165:_____/25:10504132 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/25:10504132
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=M_BaoGs09g" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=M_BaoGs09g</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.yfrne.2025.101217" target="_blank" >10.1016/j.yfrne.2025.101217</a>
Alternative languages
Result language
angličtina
Original language name
Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria
Original language description
While mitochondria provide critical energy resources, mitochondrial dysfunction can lead to both metabolic and neurodegenerative disorders. Primary mitochondrial disorders (e.g., Leigh syndrome) are uniformly associated with profound neurodegeneration. Recent studies have also implicated mitochondrial dysfunction as a central feature of progressive neurodegenerative diseases, notably Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis, and Huntington's Disease. In addition to its profound impact on metabolic disease, the glucagon-like peptide-1 receptor agonist, semaglutide, has significant neuroprotective features and may limit the progression of one or more of these disorders. These observations might be explained at least in part by the impact of this drug on mitochondrial function and energy production. Collectively, these observations highlight disrupted energy homeostasis as a critical feature of neurodegenerative disease and suggest novel targets for the development of much-needed new neuropharmaceutical strategies.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30215 - Psychiatry
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Neuroendocrinology
ISSN
0091-3022
e-ISSN
1095-6808
Volume of the periodical
79
Issue of the periodical within the volume
October
Country of publishing house
US - UNITED STATES
Number of pages
7
Pages from-to
101217
UT code for WoS article
001590527600001
EID of the result in the Scopus database
2-s2.0-105017571070